Clinical Trial Update: T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of a T cell receptor-engineered T cell therapy with a dominant negative TGF-β receptor targeting KRAS mutations in subjects with a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• KRAS-targeted TCR-T therapy with dominant negative TGF-β receptor

Snippet

Sponsor: Zhejiang University | Conditions: Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING